Side Effects Associated With Chemotherapy of Acute Lymphocytic Leukemia with Vincristine and Anthracyclines

Dr. Mohammed Shareef1, Dr. Mohammed Moizuddin2.
1Pharm D (Doctor of Pharmacy), Bhaskar Pharmacy College, Hyderabad, Telangana, India.
2Internee - Pharm D (Doctor of Pharmacy), Bhaskar Pharmacy College, Hyderabad, Telangana, India.

ABSTRACT

Background: Acute lymphocytic leukemia or acute lymphoblastic leukemia is a malignant (clonal) disease of the bone marrow in which early lymphoid precursors proliferate and replace the normal hematopoietic cells of the marrow. It is characterized by the overproduction of immature white blood cells, called lymphoblast or leukemic blasts. Chemotherapy of cancer has many side effects. Use of vincristine and anthracyclines can lead to many side effects. It may limit the efficacy of work in daily life activities of the patient. Aim: The aim of this study is to evaluate the side effects associated with the use of vincristine and anthracyclines. Methodology: This study was conducted with the objective to assess and evaluate the side effects of vincristine and anthracyclines in MNJ Institute of Oncology and Regional Cancer Centre (RCC), Lakdikapul, Hyderabad. This study is observational in nature and the subjects enrolled under this study were about 64. Informed consent was obtained from all the subjects. Subjects recruited in this study were admitted as inpatients in the hospital to receive chemotherapy. The assessment of quality of life is done by using EORTC QLQ-C30 questionnaire. Results: In this study, a total of 64 subjects with cancer were evaluated. Of 64 patients included, about 51.565 belong to age group of 0-14 years, followed by 19% in age group 15-24 years. Indicating the higher incidence of ALL in children's specifically and the family history of non-specific cancer was found in 3 patients in the study. During the study most common side effects observed were nausea (24), vomiting (22), and shortness of breath (37) and chest pain (30) which ranges from mild to moderate in severity. Conclusion: Among 64 subjects undergoing CT for ALL, out of them ALL was dominantly diagnosed in males (89%). Of 64 patients studied, 57 patients experienced leukopenia, 38 experienced neutropenia, 46 experienced thrombocytopenia and anemia in 44 patients. Thus, increased rate of transfusions (45 in males, 5 in females) attributed to decreased quality of life of patients. 1 male and 1 female died during the study, due to SOB due to bilirubinemia and non-adherence to the CT.

INTRODUCTION

Human body is made up of trillions of cells. Cancer can start anywhere in these cells. These cells start to divide uncontrollably and even spread to other cells. Sometimes these affected cells can move to far places through blood or lymph and form new tumor. The two types of cancers are benign tumors and malignant tumors. The Benign tumors are located at a particular place in the body. They do not have the ability to spread to other parts of body. Uncontrollable growth is not seen in this tumor. In Malignant tumors, the infected cells enter and destroy the organs and healthy tissues present around it. They may or may not be cancerous. In India, one women dies of cervical cancer every 8 minutes. For every 2 women newly diagnosed with breast cancer, one women dies of it in India. As many as 3500 persons die every day due to tobacco-related diseases in India. Estimated number of people living with the disease is around 2.25 million. Every year over 11 lakhs new cancer patients are registered. Cancer of oral cavity and lungs account for 25% of cancer deaths in males and cancer of breast and oral cavity accounts for 25% cancers in females. Mostly cancer is caused due to mutations in the DNA present in the cells. Other causes of cancers include, Physical activity, Diet, Exposure to harmful rays due to radiation or sun, Idiopathic causes.

the signs and symptoms of cancer vary. Mostly they appear in the form of weight loss or tiredness for more than few weeks. General signs and symptoms include: Fatigue, Appearance of a lump that can be felt, Unexplained weight loss or weight gain, Bowel or bladder habit changes, Difficulty in swallowing, Sudden onset of fever or night sweats, Trouble in breathing, Hoarseness, Changes in appearance of skin such as darkening, yellowing or redness of skin, Discomfort after eating or indigestion. Different types of cancers have different type of treatments. Various types of treatments include: Surgery, Radiation therapy, Chemo therapy, Hormone therapy, targeted therapy and Immunotherapy. Leukemia Begins in a cell in the Bone marrow. Then the cell undergoes a change and becomes a type of leukemia cell. After leukemia change, the leukemia cells may grow and survive better than normal cells. Over time, the leukemia cells suppress the development of normal cells. After diagnosis and treatment, many people with leukemia live many good, quality years. The different types of leukemia includes: Acute lymphoblastic leukemia (ALL), Acute myeloid leukemia (AML), Chronic lymphocytic leukemia (CLL), Chronic myeloid leukemia (CML), Biphenotypic acute leukemia (BAL). The other types of leukemia that are uncommonly seen are: Hair cell leukemia, T cell prolymphocytic leukemia and Juvenile myelomonocytic.
leukemia. Acute lymphocytic leukemia or acute lymphoblastic leukemia is a malignant (clonal) disease of the bone marrow in which early lymphoid precursors proliferate and replace the normal hematopoietic cells of the marrow. It is characterized by the overproduction of immature white blood cells, called lymphoblasts or leukemic blasts. These cells crowd the bone marrow, preventing it from making normal blood cells. The exact cause of ALL remain unknown but it is thought to result from mutations in one or more of the genes that normally control blood cell development. But, certain factors have been identified that may increase the risk of ALL. It includes: Previous cancer treatment, Exposure to radiation, Genetic disorders, Having a brother or sister with ALL. Signs and symptoms of ALL include: Bleeding from the gums, Bone pain, Fever, Frequent infections, Lumps caused by swollen lymph nodes in and around the neck, underarm, abdomen or groin. Shortness of breath, Blood clots, Palpable lymphadenopathy.

Vincristine is an anti-cancer chemotherapy drug. It is classified as a plant alkaloid. It can be used in the treatment of Acute leukemia, Hodgkin’s and Non-Hodgkin’s lymphoma, Neuroblastoma, Rhabdomyosarcoma, Ewing’s sarcoma, Wilms tumor, Multiple myeloma, Chronic leukemia’s, Thyroid cancer, Brain tumors. It can also be used in some types of blood cancers. Vincristine is given as intravenous infusion or intravenous injection.

Materials and Methods

Methodology

Study Site
The study was carried out at MNJ Institute of Oncology and Regional Cancer Centre (RCC)

Study Design
Prospective and Retrospective study.

Study Period
The study was conducted for 6 months (September 2018 to February 2019).

Sample Size
Patients recruited in the study with cancer were inpatients from the hospital. A total of 64 patients including 57 males and 07 females were taken and that who fulfilled the inclusion criteria.

Study Criteria

Inclusion Criteria
- Patients undergoing chemotherapy of ALL with vincristine and Anthracyclines.
- Patients who are conscious and cooperative.
- Patients who are willing to participate in the study.
- Patients of age group between 5-60 yrs.

Exclusion Criteria
- Patients with serious psychiatric illness or underwent recent surgery.
- Patients who are not conscious and communicate verbally.
- Non-compliant patients.
- Patients with co-morbid conditions.

A suitable data collection form was designed to collect, document, and analyze the data. Data collection form that includes provision to collect information like demographic details (name, age, sex), past medical history, family history, diagnostic parameters, prescribed drugs, chemotherapy induced side effects, re-visit details and contact details.

Results and Discussion

1. Distribution Based on Gender
In this study, a total of 64 patients who were diagnosed with Acute lymphocytic leukemia (ALL), among whom the majority were males, who constituted account of 89%(n=57) and females constituted 11%(n=07).

Tab1: Distribution based on Gender

| GENDER   | NO. OF PATIENTS | PERCENTAGE (%) |
|----------|-----------------|----------------|
| MALE     | 57              | 89             |
| FEMALE   | 7               | 11             |
| TOTAL    | 64              | 100            |

Distribution based on gender

Fig 1: Distribution based on Gender

2. Distribution Based on Age of the Patient
According to the age group analysis, n.o. of cases in age group of children’s (0-14) were 51.56% (n=33), Teenagers and Young adults age group (15-24) were 28.12% (n=18), Adulthood age group (25-49) were 18.75% (n=12), Late adulthood age group (50-74) were 1.44% (n=01), and elderly age group (>75) were 0 (n=0).

Tab2: Distribution based on age of the patient

| AGE GROUP            | NO. OF PATIENTS | PERCENTAGE (%) |
|----------------------|-----------------|----------------|
| Children (0-14)      | 33              | 51.56          |
| Teenagers & Young Adults (15-24) | 18          | 28.125         |
| Adulthood (25-49)    | 12              | 18.75          |
| Late Adulthood (50-74)| 1              | 1.44           |
| Elderly (>75)        | 0               | 0              |
| Total                | 64              | 100            |

Mohammed Shareef et al., World Journal of Current Med and Pharm Research., Vol-II, Iss-II, 108-119.
3. DISTRIBUTION BASED ON BLOOD PARAMETERS

According to the Blood parameters analysis, Leukocytopenia was seen in 89% (n= 57) of the patients, Neutropenia was seen in 59.3% (n= 38) of the patients, Thrombocytopenia was seen in 71.8% (n= 46) of the patients and Anemia was seen in 68.7% (n= 44) of the patients.

Tab3: Distribution based on blood parameters.

| Blood Parameter | Frequency | Percentage |
|-----------------|-----------|------------|
| Leukocytopenia  | 57        | 89         |
| Neutropenia     | 38        | 59.3       |
| Thrombocytopenia| 46        | 71.8       |
| Anemia          | 63        | 98.7       |

4. DISTRIBUTION BASED ON NUMBER OF TRANSFUSIONS:

In this study, a total of 64 patients who were diagnosed with Acute lymphocytic leukemia (ALL), among whom Females 7.81% (n= 5) and Males 70.31% (n= 45) had taken transfusions. Females 3.12% (n= 2) and Males 18.75% (n= 12) had not taken transfusions.

Tab4: Distribution based on number of transfusions

| Gender  | With Transfusions (%) | Without Transfusions (%) |
|---------|-----------------------|--------------------------|
| Females | 5 (7.81)              | 2 (3.125)                |
| Males   | 45 (70.31)            | 12 (18.75)               |

5. VINCristine and Anthracyclines dose and ROA:

Table 5: Vincristine and Anthracyclines dose and ROA.

| Drug     | Dose      | Route of administration (ROA) |
|----------|-----------|-------------------------------|
| VCR      | 1 – 1.5 mg| iv infusion / push            |
| Doxorubicin | 10-40 mg | iv / im                       |
Other drugs commonly administered during chemotherapy of ALL

| Drugs                                | Dose/Route of administration |
|--------------------------------------|------------------------------|
| Leunase (L-asparaginase)             | 1000 units/im                |
| Wysolone (prednisolone)              | 20mg/PO                      |
| Rantac (ranitidine)                  | 150mg/Po                     |
| Zofer (ondansetron)                  | 8mg/iv/PO                    |
| Endoxan (cyclophosphamide)          | 1g/iv                        |
| MTX (methotrexate)                  | 2.5mg/PO                     |
| 6-MP (6 mercaptopurine)             | 50mg/PO                      |
| Dexe (dexamethasone)                | 8mg/iv push                  |
| Tramadol                             | 50mg/PO                      |
| Zyloric (allopurinol)               | 100mg/PO                     |
| Syscan (fluconazole)                | 200mg/PO                     |

Table 6: Other drugs commonly administered during chemotherapy of ALL

6. SIDE EFFECTS

| Tab 7: Side effects |
|---------------------|
| SIDE EFFECTS        | NOT AT ALL | MILD | MODERATE | SEVERE |
| GENDER(M/F)         | M (%) | F (%) | M (%) | F (%) | M (%) | F (%) | M (%) | F (%) |
| NAUSEA              | 14.8   | 14.3  | 35.2  | 42.9  | 40.7  | 28.6  | 9.3   | 14.3  |
| VOMITING            | 13     | 42.9  | 16.7  | 0     | 38.9  | 42.9  | 31.5  | 14.3  |
| DIARRHEA            | 35.2   | 57.1  | 18.5  | 0     | 38.9  | 42.9  | 7.4   | 0     |
| MOUTHSORES          | 27.8   | 57.1  | 25.9  | 0     | 18.5  | 42.9  | 27.8  | 0     |
| SHORTNESS OF BREATH | 14.8   | 0     | 20.4  | 57.1  | 37    | 14.3  | 27.8  | 28.6  |
| CHEST PAIN          | 27.8   | 0     | 53.7  | 71.4  | 9.3   | 14.3  | 9.3   | 14.3  |
| ALOPECIA            | 35.2   | 28.6  | 27.8  | 42.9  | 16.7  | 14.3  | 20.4  | 14.3  |
| TINGLING OF LIMBS   | 42.6   | 0     | 24.1  | 14.3  | 24.1  | 71.4  | 9.3   | 14.3  |
| PAIN DURING MICTURATION | 64.8 | 42.9  | 29.6  | 57.1  | 5.6   | 0     | 0     | 0     |
| HEADACHE            | 68.5   | 57.1  | 24.1  | 42.9  | 5.6   | 0     | 1.9   | 0     |
| VISION/HEARING DISTURBANCE | 83.3 | 57.1  | 11.1  | 42.9  | 5.6   | 0     | 0     | 0     |
| LOSS OF WEIGHT      | 55.6   | 42.9  | 37    | 57.1  | 5.6   | 0     | 1.9   | 0     |
| PAIN                | 20.4   | 42.9  | 24.1  | 14.3  | 29.6  | 42.9  | 25.9  | 14.3  |
FREQUENCIES OF SIDE EFFECTS IN MALES

Fig. 5: Frequencies of side effects in Males.

FREQUENCIES OF SIDE EFFECTS IN FEMALES

Fig. 6: Frequencies of side effects in females.
A. NAUSEA IN MALES AND FEMALES

Fig. 7: Nausea in males and females

B. VOMITINGS IN MALES & FEMALES

Fig. 8: Vomiting's in males and females

C. ALOPECIA IN MALES AND FEMALES

Fig. 9: Alopecia in males and females

Mohammed Shareef et al., World Journal of Current Med and Pharm Research., Vol-II, Iss-II, 108-119.
D. MOUTHSORES IN MALES AND FEMALES

Fig.10: Mouth sores in males and females

E. SOB IN MALES AND FEMALES

Fig.11: SOB in males and females

F. CHESTPAIN IN MALES AND FEMALES

Fig.12: Chest pain in males and females
G. DIARRHEA IN MALES & FEMALES

Fig.13: Mouth sores in males and females

H. TINGLING OF LIMBS IN MALES & FEMALES

Fig.14: Tingling of limbs in males and females

I. PAIN DURING MICTURITION IN MALES AND FEMALES

Fig.15: Pain during micturition in males and females

Mohammed Shareef et al., World Journal of Current Med and Pharm Research., Vol-II, Iss-II, 108-119.
J. FATIGUE IN MALES AND FEMALES

Fig.16: Fatigue in males and females

K. HEADACHE IN MALES & FEMALES

Fig.17: Headache in males and females

L. VISION/HEARING DISTURBANCES IN MALES & FEMALES

Fig.18: Vision/hearing disturbances in males and females

Mohammed Shareef et al., World Journal of Current Med and Pharm Research., Vol-II, Iss-II, 108-119.
M. LOSS OF WEIGHT IN MALES AND FEMALES

Fig. 19: Loss of weight in males and females

N. PAIN IN MALES AND FEMALES

Fig. 20: Pain in males and females

7. MORTALITY RATE:

Table 8: Mortality rate

| GENDER | NO. OF PATIENTS EXPIRED | PERCENTAGE(%) |
|--------|-------------------------|---------------|
| MALES  | 1                       | 1.56          |
| FEMALES| 1                       | 1.56          |
| TOTAL  | 64                      | 100           |

Fig. 21: Mortality rate
8. DISTRIBUTION BASED ON FAMILY HISTORY

| FAMILY HISTORY | NO. OF PATIENTS | PERCENTAGE (%) |
|----------------|----------------|----------------|
| GENDER         | MALES | FEMALES | MALES | FEMALES |
| PATIENTS WITH RELEVANT HISTORY | 2     | 1      | 3.12  | 1.56    |
| PATIENTS WITHOUT RELEVANT HISTORY | 55    | 6      | 85.93 | 9.37    |
| TOTAL NO. OF PATIENTS | 64    |        | 100   |         |

Fig.22: Distribution based on family history

CONCLUSION
We have conducted a prospective observational study including a total of 64 patients for a period of 6 months. Among 64 subjects undergoing CT for ALL, out of them ALL was dominantly diagnosed in males (89%). The incidence of ALL was also found more significantly in children of age group 0-14 years (33%), followed by it is the age group 15-24 years (18%). Of 64 patients studied, 57 patients experienced leukocytopenia, 38 experienced neutropenia, 46 experienced thrombocytopenia and anemia in 44 patients. Thus, increased rate of transfusions (45 in males, 5 in females) attributed to decreased quality of life of patients. 1 male and 1 female died during the study, due to SOB due to bilirubinemia and non-adherence to the CT. After analysis of collected data, it can be concluded that among various side effects associated with administration of VCR and ATC’s, the most common side effects were nausea, vomiting, shortness of breath, chest pain, alopecia, mouth-sores. All of these side effects however are mostly reversible and last only for a particular period of time(up to a week) during the course of chemotherapy. Although encountering many side effects, with the administration of VCR and ATC’s during the chemotherapy of acute lymphocytic leukemia, the patient’s recovery is found to be effective, provided strictly adherent to all phases of chemotherapy. It can be concluded from the study that it requires detection and reporting of side effects and educating the patient regarding the side effects.

So, as to improve the patients’ perceptions and management of side effects thus improving overall quality of life of patients.

ACKNOWLEDGEMENT
First and foremost, we would thank to the ALMIGHTY GOD for giving us the strength, knowledge, ability and opportunity to undertake this research study and to persevere and complete it satisfactorily. We would like to thank my PARENTS for their wise counsel and sympathetic ear and supporting us at each step for conduction and completion of dissertation. We would like to express my sincere gratitude to Dr. Srinivasa Rao, Principal, Bhaskar Pharmacy College. His words of advice have been etched in our heart and we will always endeavor to hold up his ideas. We thank you sir for encouraging out the best in me. We owe my humble thanks to Associate professor Dr. A. V. Kishore Babu, B. Pharm, Pharm. D (PB), Ph.D., H.O.D, Department of Pharmacy practice, for his valuable guidance, advice and encouragement. I express my sincere gratitude to Mrs. Sabitha Sahoo, Assistant Professor, who have been inspirational and supportive throughout our work undertaken and endowed us with the most precious knowledge to see success in my endeavor. I greatly acknowledge to Dr. Sudha Sinha, Consultant Medical Oncologist, MNJ Institute Of Medical Oncology and Regional Cancer Centre, Lakdikapool, Hyderabad for her valuable help throughout my research.
Research Article

In short, we would like to thank each and every member associated with our study for their valuable support and deliberating over our problems and findings.

BIBLIOGRAPHY

1. What is cancer? https://www.cancer.gov/about-cancer/understanding/what-is-cancer/: Feb 9 2015
2. Cancer: Symptoms, Causes, Diagnosis, Classification and Management, https://www.aimu.us/2016/10/20/cancer-symptoms-causes-diagnosis-classification-and-management/: Oct 20 2016.
3. India against cancer statistics. https://cancerindia.org.in/statistics/: March 2, 2020.
4. Cancer. https://www.mayoclinic.org/diseases-conditions/cancer/symptoms-causes/syc-20370588.
5. Essentials of medical pharmacology. KD. Tripathi. Seventh edition.
6. Types of cancer treatment. https://www.cancer.gov/about-cancer/treatment/types.
7. Leukemia. https://www.lls.org/leukemia:
8. ALL. https://www.leukaemia.org.au/blood-cancers/leukaemias/acute-lymphoblastic-leukaemia-all: June 18, 2019
9. Vincristine and its side effects. https://chemocare.com/chemotherapy/drug-info/vincristine.aspx:
10. Anthracyclines. https://chemoth.com/types/anthracyclines: